Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment.

Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP.

Sci Rep. 2019 May 10;9(1):7202. doi: 10.1038/s41598-019-43627-3.

2.

Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.

Hsiao HY, Chiu FL, Chen CM, Wu YR, Chen HM, Chen YC, Kuo HC, Chern Y.

Hum Mol Genet. 2014 Aug 15;23(16):4328-44. doi: 10.1093/hmg/ddu151. Epub 2014 Apr 3.

PMID:
24698979
3.

Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.

Liu SY, Yu XL, Zhu J, Liu XM, Zhang Y, Dong QX, Ma S, Liu RT.

Brain Res. 2018 Oct 15;1697:21-33. doi: 10.1016/j.brainres.2018.06.009. Epub 2018 Jun 11.

PMID:
29902468
4.

A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.

Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y.

Hum Mol Genet. 2013 May 1;22(9):1826-42. doi: 10.1093/hmg/ddt036. Epub 2013 Jan 30.

PMID:
23372043
5.

Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP.

PLoS One. 2009 Nov 30;4(11):e8025. doi: 10.1371/journal.pone.0008025.

6.

Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.

Rué L, Bañez-Coronel M, Creus-Muncunill J, Giralt A, Alcalá-Vida R, Mentxaka G, Kagerbauer B, Zomeño-Abellán MT, Aranda Z, Venturi V, Pérez-Navarro E, Estivill X, Martí E.

J Clin Invest. 2016 Nov 1;126(11):4319-4330. doi: 10.1172/JCI83185. Epub 2016 Oct 10.

7.

Plasma inflammatory biomarkers for Huntington's disease patients and mouse model.

Chang KH, Wu YR, Chen YC, Chen CM.

Brain Behav Immun. 2015 Feb;44:121-7. doi: 10.1016/j.bbi.2014.09.011. Epub 2014 Sep 28.

PMID:
25266150
8.

AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.

Ju TC, Chen HM, Chen YC, Chang CP, Chang C, Chern Y.

Biochim Biophys Acta. 2014 Sep;1842(9):1668-80. doi: 10.1016/j.bbadis.2014.06.012. Epub 2014 Jun 16.

9.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

10.

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.

Fatoba O, Kloster E, Reick C, Saft C, Gold R, Epplen JT, Arning L, Ellrichmann G.

Exp Neurol. 2018 Apr;302:112-128. doi: 10.1016/j.expneurol.2018.01.001. Epub 2018 Jan 6.

PMID:
29309751
11.

iNKT Cell Activation Exacerbates the Development of Huntington's Disease in R6/2 Transgenic Mice.

Park HJ, Lee SW, Im W, Kim M, Van Kaer L, Hong S.

Mediators Inflamm. 2019 Jan 15;2019:3540974. doi: 10.1155/2019/3540974. eCollection 2019.

12.

Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB.

J Huntingtons Dis. 2015;4(1):17-36.

13.

Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.

Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M.

PLoS One. 2013 Dec 19;8(12):e84726. doi: 10.1371/journal.pone.0084726. eCollection 2013.

14.

IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.

Duarte AI, Petit GH, Ranganathan S, Li JY, Oliveira CR, Brundin P, Björkqvist M, Rego AC.

Exp Neurol. 2011 Oct;231(2):314-9. doi: 10.1016/j.expneurol.2011.06.016. Epub 2011 Jul 7.

PMID:
21763311
15.

Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.

Berggren KL, Chen J, Fox J, Miller J, Dodds L, Dugas B, Vargas L, Lothian A, McAllum E, Volitakis I, Roberts B, Bush AI, Fox JH.

Redox Biol. 2015;4:363-74. doi: 10.1016/j.redox.2015.02.002. Epub 2015 Feb 11.

16.

A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, Zhu C, Ando TK, André VM, Cepeda C, Watson JB, Levine MS.

J Neurophysiol. 2012 Jan;107(2):677-91. doi: 10.1152/jn.00762.2011. Epub 2011 Nov 9.

17.

Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models.

Träger U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdžić E, Smith DL, Leavitt BR, Bates GP, Björkqvist M, Tabrizi SJ.

Neurobiol Dis. 2015 Jan;73:388-98. doi: 10.1016/j.nbd.2014.10.012. Epub 2014 Oct 29.

18.

Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.

Bobrowska A, Paganetti P, Matthias P, Bates GP.

PLoS One. 2011;6(6):e20696. doi: 10.1371/journal.pone.0020696. Epub 2011 Jun 3.

19.

Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.

Wang SE, Lin CL, Hsu CH, Sheu SJ, Chien CT, Wu CH.

Drug Des Devel Ther. 2015 Feb 16;9:887-900. doi: 10.2147/DDDT.S78015. eCollection 2015.

20.

Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.

Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ.

J Neurosci. 2004 Mar 3;24(9):2270-6.

Supplemental Content

Support Center